Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.

Gregory T Wurz, Chiao-Jung Kao, Michael Wolf, Michael W DeGregorio, Tecemotide: An antigen-specific cancer immunotherapy Human Vaccines & Immunotherapeutics. ,vol. 10, pp. 3383- 3393 ,(2014) , 10.4161/HV.29836

Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020

Marina Spivak, Jason Weston, Léon Bottou, Lukas Käll, William Stafford Noble, Improvements to the Percolator Algorithm for Peptide Identification from Shotgun Proteomics Data Sets Journal of Proteome Research. ,vol. 8, pp. 3737- 3745 ,(2009) , 10.1021/PR801109K

Andrea Bertotti, Giorgia Migliardi, Francesco Galimi, Francesco Sassi, Davide Torti, Claudio Isella, Davide Corà, Federica Di Nicolantonio, Michela Buscarino, Consalvo Petti, Dario Ribero, Nadia Russolillo, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Luca Molinaro, Emanuele Valtorta, Andrea Sartore-Bianchi, Mauro Risio, Lorenzo Capussotti, Marcello Gambacorta, Salvatore Siena, Enzo Medico, Anna Sapino, Silvia Marsoni, Paolo M Comoglio, Alberto Bardelli, Livio Trusolino, None, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery. ,vol. 1, pp. 508- 523 ,(2011) , 10.1158/2159-8290.CD-11-0109

Lei Zheng, Barish H. Edil, Kevin C. Soares, Khaled El-Shami, Jennifer N. Uram, Carol Judkins, Zhe Zhang, Beth Onners, Daniel Laheru, Drew Pardoll, Elizabeth M. Jaffee, Richard D. Schulick, A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte–Macrophage Colony Stimulating Factor–Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer Annals of Surgical Oncology. ,vol. 21, pp. 3931- 3937 ,(2014) , 10.1245/S10434-014-3844-X

J. T. Garrett, M. G. Olivares, C. Rinehart, N. D. Granja-Ingram, V. Sanchez, A. Chakrabarty, B. Dave, R. S. Cook, W. Pao, E. McKinely, H. C. Manning, J. Chang, C. L. Arteaga, Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase Proceedings of the National Academy of Sciences of the United States of America. ,vol. 108, pp. 5021- 5026 ,(2011) , 10.1073/PNAS.1016140108

A Lugli, I Zlobec, K Baker, P Minoo, L Tornillo, L Terracciano, J R Jass, Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair status Journal of Clinical Pathology. ,vol. 60, pp. 534- 539 ,(2006) , 10.1136/JCP.2006.039552

Deepak Raina, Yasumitsu Uchida, Akriti Kharbanda, Hasan Rajabi, Govind Panchamoorthy, Caining Jin, Surender Kharbanda, Maurizio Scaltriti, Jose Baselga, Donald Kufe, None, TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS Oncogene. ,vol. 33, pp. 3422- 3431 ,(2014) , 10.1038/ONC.2013.308

Katrien Berns, Hugo M. Horlings, Bryan T. Hennessy, Mandy Madiredjo, E. Marielle Hijmans, Karin Beelen, Sabine C. Linn, Ana Maria Gonzalez-Angulo, Katherine Stemke-Hale, Michael Hauptmann, Roderick L. Beijersbergen, Gordon B. Mills, Marc J. van de Vijver, René Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. ,vol. 12, pp. 395- 402 ,(2007) , 10.1016/J.CCR.2007.08.030

David L. Shattuck, Jamie K. Miller, Kermit L. Carraway, Colleen Sweeney, Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Research. ,vol. 68, pp. 1471- 1477 ,(2008) , 10.1158/0008-5472.CAN-07-5962